Silicon Laboratories Inc (SLAB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2027, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLAB SEC filings page.
Silicon Laboratories Inc (SLAB) reported $855.9M in revenue over the twelve months to Jul 4, 2026, up 21.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovery is rebuilding gross profit, but heavy operating spending still prevents that improvement from reaching earnings.
Revenue recovered in FY2025, but operating margin remained-9.0% ; the top-line rebound therefore has not yet absorbed the cost structure. Meanwhile, operating cash flow returned to$95.7M while free cash flow was$65.8M , indicating that noncash charges and working-capital movement cushioned accounting losses, with capital spending consuming part of the cash generated.
The balance sheet has compressed materially, with total assets falling from
R&D consumed
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Silicon Laboratories Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Silicon Laboratories Inc held $443.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $95.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Silicon Laboratories Inc scores 85/100 among other emerging companies.
Silicon Laboratories Inc had 33M shares outstanding at the end of fiscal year 2025, against 32M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Silicon Laboratories Inc scores 66/100 among other emerging companies.
Silicon Laboratories Inc spent $353.2M on research and development in fiscal year 2025, which was 41.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Silicon Laboratories Inc scores 72/100 among other emerging companies.
Silicon Laboratories Inc reported revenue of $784.8M in fiscal year 2025, against $584.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Silicon Laboratories Inc scores 44/100 among other emerging companies.
Silicon Laboratories Inc's operations generated $95.7M of cash in fiscal year 2025, against $13.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Silicon Laboratories Inc scores 98/100 among other emerging companies.
Silicon Laboratories Inc's cash, cash equivalents and investments came to $443.6M at the end of fiscal year 2025, against $174.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Silicon Laboratories Inc scores 79/100 among other emerging companies.
Silicon Laboratories Inc scores 27.19, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($7.4B) relative to total liabilities ($174.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silicon Laboratories Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Silicon Laboratories Inc reported a net loss of $64.9M while generating $95.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Silicon Laboratories Inc reported an operating loss of $70.5M against $975K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Silicon Laboratories Inc generated $228.2M in revenue in Q2 2027. This represents an increase of 18.3% from the same quarter a year earlier. Against the prior quarter it is up 6.9%.
Silicon Laboratories Inc's EBITDA was -$4.5M in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.3% from the same quarter a year earlier. Against the prior quarter it is up 58.8%.
Silicon Laboratories Inc reported -$10.6M in net income in Q2 2027. This represents an increase of 51.5% from the same quarter a year earlier. Against the prior quarter it is up 33.4%.
Silicon Laboratories Inc earned -$0.32 per diluted share (EPS) in Q2 2027. This represents an increase of 52.2% from the same quarter a year earlier. Against the prior quarter it is up 33.3%.
Cash & Balance Sheet
Silicon Laboratories Inc recorded an outflow of $26.8M in free cash flow in Q2 2027, representing a cash shortfall after capex. This represents a decrease of 608.0% from the same quarter a year earlier. Against the prior quarter it is down 447.2%.
Silicon Laboratories Inc held $362.2M in cash as of Q2 2027; long-term debt is not reported for that period.
Not reported for Q2 2027.
Margins & Returns
Silicon Laboratories Inc's gross margin was 61.7% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.
Silicon Laboratories Inc's operating margin was -4.7% in Q2 2027, reflecting core business profitability. This is up 7.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.3 percentage points.
Silicon Laboratories Inc's net profit margin was -4.6% in Q2 2027, showing the share of revenue converted to profit. This is up 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.
Silicon Laboratories Inc's ROE was -1.0% in Q2 2027, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
Silicon Laboratories Inc invested $95.0M in research and development in Q2 2027. This represents an increase of 8.2% from the same quarter a year earlier. Against the prior quarter it is up 7.2%.
Silicon Laboratories Inc invested $12.3M in capex in Q2 2027, funding long-term assets and infrastructure. This represents an increase of 41.6% from the same quarter a year earlier. Against the prior quarter it is up 25.2%.
Not reported for Q2 2027.
SLAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $228.2M+18.3% | $213.5M+20.1% | $208.2M+25.2% | $206.0M+23.8% | $192.8M+32.7% | $177.7M+67.1% | $166.2M+91.4% | $166.4M-18.3% |
| Cost of Revenue | $87.5M+3.3% | $86.5M+8.2% | $76.1M+0.1% | $87.0M+14.3% | $84.7M+23.2% | $79.9M+55.8% | $76.0M+77.1% | $76.1M-10.2% |
| Gross Profit | $140.7M+30.1% | $127.0M+29.9% | $132.1M+46.4% | $119.0M+31.8% | $108.1M+41.2% | $97.8M+77.6% | $90.2M+105.4% | $90.3M-24.1% |
| R&D Expenses | $95.0M+8.2% | $88.6M+0.4% | $89.5M+8.6% | $87.7M+5.4% | $87.8M+2.2% | $88.2M+9.4% | $82.4M-1.2% | $83.2M+5.3% |
| SG&A Expenses | $56.3M+30.5% | $55.5M+33.3% | $45.8M+25.8% | $43.7M+18.7% | $43.2M+11.5% | $41.6M+24.1% | $36.4M+8.3% | $36.8M+32.5% |
| Operating Income | -$10.7M+53.4% | -$17.1M+46.8% | -$3.3M+88.6% | -$12.3M+58.5% | -$22.9M+52.4% | -$32.1M+45.8% | -$28.6M+60.8% | -$29.7M-343.2% |
| EBITDA | -$4.5M+72.3% | -$11.0M+57.3% | $16.1M+2348.8% | -$6.3M+73.4% | -$16.4M+60.5% | -$25.8M+50.8% | $656K+101.6% | -$23.6M-225.5% |
| Interest Expense | $251K0.0% | $232K-18.3% | $214K-17.7% | $226K-18.7% | $251K-4.6% | $284K-44.2% | $260K-72.4% | $278K-79.5% |
| Income Tax | $2.2M-14.5% | $2.2M+16.3% | $2.1M+203.1% | $414K-79.4% | $2.5M-93.1% | $1.9M+593.2% | -$2.1M+86.6% | $2.0M-40.8% |
| Net Income | -$10.6M+51.5% | -$15.9M+47.8% | -$2.7M+88.7% | -$9.9M+65.1% | -$21.8M+73.4% | -$30.5M+46.1% | -$23.8M+65.9% | -$28.5M-375.5% |
| EPS (Basic) | -$0.32+52.2% | -$0.48+48.9% | -$0.07+90.3% | -$0.30+65.9% | -$0.67+73.8% | -$0.94+46.9% | -$0.72+67.3% | -$0.88-366.7% |
| EPS (Diluted) | -$0.32+52.2% | -$0.48+48.9% | -$0.07+90.3% | -$0.30+65.9% | -$0.67+73.8% | -$0.94+46.9% | -$0.72+66.7% | -$0.88-375.0% |
| Diluted Shares (Avg) | 33M+1.6% | 33M+1.5% | N/A | 33M+1.6% | 33M+1.7% | 32M+1.7% | N/A | 32M+0.7% |
SLAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B+2.6% | $1.3B+3.0% | $1.3B+3.8% | $1.3B+0.3% | $1.2B-2.3% | $1.2B-8.5% | $1.2B-15.3% | $1.2B-15.3% |
| Current Assets | $671.2M+8.7% | $676.3M+9.3% | $674.0M+12.0% | $652.6M+6.3% | $617.7M+3.0% | $618.7M-4.2% | $602.0M-18.4% | $614.1M-20.6% |
| Cash & Equivalents | $362.2M+15.2% | $383.1M+17.9% | $364.2M+29.3% | $341.4M+12.6% | $314.5M+30.6% | $324.9M+69.7% | $281.6M+23.8% | $303.1M+89.5% |
| Short-Term Investments | $35.1M-65.3% | $55.8M-44.2% | $79.4M-21.0% | $97.6M+46.6% | $101.1M+2.8% | $99.9M-29.2% | $100.6M-52.5% | $66.6M-74.1% |
| Inventory | $123.3M+52.5% | $103.2M+23.8% | $95.6M-9.5% | $82.2M-41.1% | $80.9M-51.3% | $83.4M-57.9% | $105.6M-45.6% | $139.5M-16.8% |
| Accounts Receivable | $79.8M+41.3% | $77.1M+48.1% | $64.5M+18.4% | $67.3M+37.7% | $56.5M+37.1% | $52.1M+59.6% | $54.5M+86.0% | $48.9M-52.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% | $376.4M0.0% |
| Total Liabilities | $158.3M-1.1% | $167.9M+4.3% | $174.9M+22.6% | $182.4M+8.6% | $160.0M+1.9% | $161.1M-9.8% | $142.7M-39.1% | $167.9M-22.0% |
| Current Liabilities | $124.1M+2.9% | $132.5M+10.7% | $143.8M+46.9% | $145.3M+22.8% | $120.7M+20.5% | $119.7M+7.5% | $97.9M-40.2% | $118.3M-28.4% |
| Non-Current Liabilities | $34.1M-13.2% | $35.4M-14.3% | $31.1M-30.5% | $37.0M-25.2% | $39.3M-30.8% | $41.4M-38.5% | $44.8M-36.8% | $49.6M-0.9% |
| Total Equity | $1.1B+3.2% | $1.1B+2.8% | $1.1B+1.3% | $1.1B-1.0% | $1.1B-2.9% | $1.1B-8.3% | $1.1B-10.6% | $1.1B-14.2% |
| Retained Earnings | $910.3M-4.1% | $920.9M-5.2% | $936.8M-6.5% | $939.5M-8.4% | $949.4M-9.9% | $971.3M-14.5% | $1.0B-16.0% | $1.0B-18.8% |
Not reported in any period shown, so not listed: Long-Term Debt.
SLAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.5M-395.7% | $4.9M-89.7% | $8.3M-17.6% | $34.3M+8.5% | $4.9M-69.6% | $48.1M+167.0% | $10.1M-45.4% | $31.6M+194.7% |
| Depreciation & Amortization | $6.1M-5.1% | $6.0M-3.2% | $5.9M-4.8% | $6.1M-1.3% | $6.5M-1.0% | $6.2M-5.8% | $6.2M-6.9% | $6.2M-6.1% |
| Stock-Based Compensation | $25.6M+28.9% | $21.1M+6.8% | N/A | $20.0M+26.0% | $19.9M+25.5% | $19.7M+44.8% | N/A | $15.9M+174.7% |
| Capital Expenditures | $12.3M+41.6% | $9.8M+102.7% | $10.0M+151.8% | $6.4M+189.5% | $8.7M+146.4% | $4.9M+137.0% | $4.0M+5.7% | $2.2M-56.5% |
| Free Cash Flow | -$26.8M-608.0% | -$4.9M-111.3% | -$1.6M-126.4% | $27.9M-5.1% | -$3.8M-130.1% | $43.3M+158.6% | $6.2M-58.3% | $29.4M+176.5% |
| Investing Cash Flow | $12.3M+221.7% | $14.9M+481.8% | $8.8M+123.0% | -$6.8M-122.4% | -$10.2M-125.6% | -$3.9M-104.8% | -$38.2M-188.0% | $30.2M+193.9% |
| Financing Cash Flow | -$18.7M-262.0% | -$956K+0.2% | $5.7M-13.5% | -$627K-248.2% | -$5.2M+19.1% | -$958K+97.9% | $6.6M+16.4% | $423K+100.8% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $16K | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid.
SLAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.7%+5.6pp | 59.5%+4.5pp | 63.4%+9.2pp | 57.8%+3.5pp | 56.1%+3.4pp | 55.0%+3.2pp | 54.3%+3.7pp | 54.3%-4.1pp |
| Operating Margin | -4.7%+7.2pp | -8.0%+10.0pp | -1.6%+15.7pp | -6.0%+11.9pp | -11.9%+21.2pp | -18.1%+37.5pp | -17.2%+67.0pp | -17.8%-23.8pp |
| Net Margin | -4.6%+6.7pp | -7.4%+9.7pp | -1.3%+13.0pp | -4.8%+12.3pp | -11.3%+45.2pp | -17.2%+36.0pp | -14.3%+66.0pp | -17.1%-22.2pp |
| Return on Equity | -1.0%+1.1pp | -1.5%+1.4pp | -0.2%+2.0pp | -0.9%+1.7pp | -2.1%+5.5pp | -2.9%+2.0pp | -2.2%+3.6pp | -2.6%-3.5pp |
| Return on Assets | -0.9%+0.9pp | -1.3%+1.2pp | -0.2%+1.7pp | -0.8%+1.5pp | -1.8%+4.8pp | -2.5%+1.7pp | -1.9%+2.9pp | -2.3%-3.0pp |
| Current Ratio | 5.41+0.3x | 5.11-0.1x | 4.69-1.5x | 4.49-0.7x | 5.12-0.9x | 5.17-0.6x | 6.15+1.6x | 5.19+0.5x |
| Debt-to-Equity | 0.140.0x | 0.150.0x | 0.160.0x | 0.170.0x | 0.150.0x | 0.150.0x | 0.13-0.1x | 0.160.0x |
| Asset Turnover | 0.180.0x | 0.170.0x | 0.160.0x | 0.160.0x | 0.160.0x | 0.14+0.1x | 0.14+0.1x | 0.130.0x |
| FCF Margin | -11.8%-9.8pp | -2.3%-26.7pp | -0.8%-4.5pp | 13.6%-4.1pp | -2.0%-10.6pp | 24.3%+93.8pp | 3.7%-13.3pp | 17.7%+36.6pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Silicon Laboratories Inc SLAB | FY2025 | $784.8M | -$64.9M | -8.3% | $7.4B | 74/100 |
| Semtech Corp SMTC | FY2026 | $1.0B | -$40.4M | -3.9% | $14.9B | 38/100 |
| Allegro MicroSystems, Inc. ALGM | FY2026 | $890.1M | -$14.7M | -1.7% | $6.6B | 47/100 |
| Cirrus Logic Inc CRUS | FY2026 | $2.0B | $414.4M | 20.8% | $5.8B | 82/100 |
| Impinj, Inc. PI | FY2025 | $361.1M | -$10.8M | -3.0% | $5.2B | 45/100 |
| Synaptics Inc SYNA | FY2026 | $1.2B | -$490.8M | -41.0% | $3.7B | 37/100 |
Where Silicon Laboratories Inc Ranks
Frequently Asked Questions
What is Silicon Laboratories Inc's annual revenue?
Silicon Laboratories Inc (SLAB) reported $784.8M in total revenue for fiscal year 2025. This represents a 34.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silicon Laboratories Inc's revenue growing?
Silicon Laboratories Inc (SLAB) revenue grew by 34.3% year-over-year, from $584.4M to $784.8M in fiscal year 2025.
Is Silicon Laboratories Inc profitable?
No, Silicon Laboratories Inc (SLAB) reported a net income of -$64.9M in fiscal year 2025, with a net profit margin of -8.3%.
What is Silicon Laboratories Inc's EBITDA?
Silicon Laboratories Inc (SLAB) had EBITDA of -$32.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silicon Laboratories Inc's gross margin?
Silicon Laboratories Inc (SLAB) had a gross margin of 58.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Silicon Laboratories Inc's operating margin?
Silicon Laboratories Inc (SLAB) had an operating margin of -9.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Silicon Laboratories Inc's net profit margin?
Silicon Laboratories Inc (SLAB) had a net profit margin of -8.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Silicon Laboratories Inc's return on equity (ROE)?
Silicon Laboratories Inc (SLAB) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silicon Laboratories Inc's free cash flow?
Silicon Laboratories Inc (SLAB) generated $65.8M in free cash flow during fiscal year 2025. This represents a 356.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silicon Laboratories Inc's operating cash flow?
Silicon Laboratories Inc (SLAB) generated $95.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Silicon Laboratories Inc's total assets?
Silicon Laboratories Inc (SLAB) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Silicon Laboratories Inc's capital expenditures?
Silicon Laboratories Inc (SLAB) invested $29.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Silicon Laboratories Inc spend on research and development?
Silicon Laboratories Inc (SLAB) invested $353.2M in research and development during fiscal year 2025.
What is Silicon Laboratories Inc's current ratio?
Silicon Laboratories Inc (SLAB) had a current ratio of 4.69 as of fiscal year 2025, which is generally considered healthy.
What is Silicon Laboratories Inc's debt-to-equity ratio?
Silicon Laboratories Inc (SLAB) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silicon Laboratories Inc's return on assets (ROA)?
Silicon Laboratories Inc (SLAB) had a return on assets of -5.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silicon Laboratories Inc's P/E ratio?
Silicon Laboratories Inc (SLAB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to July 4, 2026). The market capitalization is $7.4B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Silicon Laboratories Inc's price-to-sales ratio?
Silicon Laboratories Inc (SLAB) trades at 8.6x sales, its market capitalization divided by revenue of $855.9M revenue, trailing 12 months to July 4, 2026. The market capitalization is $7.4B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Silicon Laboratories Inc's Altman Z-Score?
Silicon Laboratories Inc (SLAB) has an Altman Z-Score of 27.19, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Silicon Laboratories Inc's Piotroski F-Score?
Silicon Laboratories Inc (SLAB) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silicon Laboratories Inc's earnings high quality?
Silicon Laboratories Inc (SLAB) reported a net loss of $64.9M while generating $95.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Silicon Laboratories Inc cover its interest payments?
Silicon Laboratories Inc (SLAB) reported an operating loss of $70.5M against $975K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Silicon Laboratories Inc?
Silicon Laboratories Inc (SLAB) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.